Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.06% | 19.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.02% | -8.09% | |||
| Operating Income | -26.02% | 8.09% | |||
| Income Before Tax | -28.83% | 7.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.83% | 7.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.83% | 7.81% | |||
| EBIT | -26.02% | 8.09% | |||
| EBITDA | -26.08% | 8.14% | |||
| EPS Basic | -19.54% | 8.81% | |||
| Normalized Basic EPS | -19.53% | 8.79% | |||
| EPS Diluted | -19.54% | 8.81% | |||
| Normalized Diluted EPS | -19.53% | 8.79% | |||
| Average Basic Shares Outstanding | 7.78% | 1.09% | |||
| Average Diluted Shares Outstanding | 7.78% | 1.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||